<DOC>
	<DOCNO>NCT00674856</DOCNO>
	<brief_summary>To study pharmacokinetics safety naproxcinod patient impaired renal function</brief_summary>
	<brief_title>A Pharmacokinetics Safety Study Naproxcinod Subjects With Impaired Renal Function</brief_title>
	<detailed_description>This 8-day , repeat dose , open label study investigate pharmacokinetics safety naproxcinod order guide initial dose achieve optimal dose naproxcinod Renal impair patient .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Naproxen-n-butyl nitrate</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Male female age 18 75 year stable mild moderate renal insufficiency . Male female age 18 75 year similar distribution age , weight , gender , smoke habit , race , general good health Any significant acute chronic disease ( except renal impairment ) may interfere study evaluation . A history alcohol drug abuse . Diagnosis gastric duodenal ulceration and/or history significant gastroduodenal bleeding within last 6 month Clinically relevant abnormal ECG Current expect use anticoagulant analgesic , antiinflammatory therapy except low dose aspirin ( less equal 325mg per day ) . Participation within 30 day prior screen another investigational study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>